A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN

NCT04032093

Last updated date
Study Location
Hospital Clinico Universidad de Chile
Santiago, Region Metropolitana, 8380456, Chile
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Respiratory Tract Infection
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-49 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Maternal participants:

- Healthy women 18 to 49 years of age between 24 and 36 weeks of gestation on the day of planned vaccination, with an uncomplicated pregnancy, who are at no known increased risk for complications, and whose fetus has no significant abnormalities observed on ultrasound.

- Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

- Receiving prenatal standard of care.

- Had an ultrasound performed at >=18 weeks of pregnancy.

- Had a negative urinalysis for protein and glucose at the screening visit. Trace protein in the urine is acceptable if the blood pressure is also normal.

- Determined by medical history, physical examination, screening laboratory assessment, and clinical judgment to be appropriate for inclusion in the study.

- Documented negative human immunodeficiency virus antibody, hepatitis B virus surface antigen, hepatitis C virus antibody, and syphilis tests at the screening visit.

- Body mass index of

- Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent document and in this protocol.

- Expected to be available for the duration of the study and willing to give informed consent for her infant to participate in the study.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Infant Participants:


• Infant who is a direct descendant (eg, child or grandchild) of the study personnel.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Respiratory Tract InfectionA Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.
NCT04424316
  1. Rosario, Santa FE
  2. Porto Alegre, RS
  3. Porto Alegre, RS
  4. Halifax, Nova Scotia
  5. Fajara, KMC,
  6. Nakagami-gun, Okinawa
  7. Auckland,
  8. Birmingham, Alabama
  9. Birmingham, Alabama
  10. Birmingham, Alabama
  11. Birmingham, Alabama
  12. Birmingham, Alabama
  13. Birmingham, Alabama
  14. Birmingham, Alabama
  15. Birmingham, Alabama
  16. Cullman, Alabama
  17. Cullman, Alabama
  18. Cullman, Alabama
  19. Mobile, Alabama
  20. Mobile, Alabama
  21. Mobile, Alabama
  22. Phoenix, Arizona
  23. Phoenix, Arizona
  24. Phoenix, Arizona
  25. Tucson, Arizona
  26. Tucson, Arizona
  27. Tucson, Arizona
  28. Tucson, Arizona
  29. Tucson, Arizona
  30. Jonesboro, Arkansas
  31. Jonesboro, Arkansas
  32. Jonesboro, Arkansas
  33. Jonesboro, Arkansas
  34. Chowchilla, California
  35. Huntington Park, California
  36. Huntington Park, California
  37. Huntington Park, California
  38. Lancaster, California
  39. Lancaster, California
  40. Loma Linda, California
  41. Loma Linda, California
  42. Loma Linda, California
  43. Loma Linda, California
  44. Loma Linda, California
  45. Long Beach, California
  46. Long Beach, California
  47. Long Beach, California
  48. Los Angeles, California
  49. Los Angeles, California
  50. Los Angeles, California
  51. Los Angeles, California
  52. Los Angeles, California
  53. Los Angeles, California
  54. Los Angeles, California
  55. Los Angeles, California
  56. Madera, California
  57. Madera, California
  58. Madera, California
  59. Madera, California
  60. Santa Monica, California
  61. Santa Monica, California
  62. Santa Monica, California
  63. Stanford, California
  64. Thousand Oaks, California
  65. Ventura, California
  66. Aurora, Colorado
  67. Aurora, Colorado
  68. Aurora, Colorado
  69. Aurora, Colorado
  70. Aurora, Colorado
  71. Aurora, Colorado
  72. Aurora, Colorado
  73. Aurora, Colorado
  74. Delta, Colorado
  75. Fruita, Colorado
  76. Grand Junction, Colorado
  77. Grand Junction, Colorado
  78. Grand Junction, Colorado
  79. Grand Junction, Colorado
  80. Grand Junction, Colorado
  81. Montrose, Colorado
  82. Washington, District of Columbia
  83. Washington, District of Columbia
  84. Washington, District of Columbia
  85. Loxahatchee Groves, Florida
  86. Miami, Florida
  87. North Miami Beach, Florida
  88. North Miami Beach, Florida
  89. Panama City, Florida
  90. Panama City, Florida
  91. Panama City, Florida
  92. Panama City, Florida
  93. Pembroke Pines, Florida
  94. Pembroke Pines, Florida
  95. Atlanta, Georgia
  96. Atlanta, Georgia
  97. Atlanta, Georgia
  98. Atlanta, Georgia
  99. Augusta, Georgia
  100. Augusta, Georgia
  101. Columbus, Georgia
  102. Columbus, Georgia
  103. Blackfoot, Idaho
  104. Blackfoot, Idaho
  105. Blackfoot, Idaho
  106. Idaho Falls, Idaho
  107. Idaho Falls, Idaho
  108. Nampa, Idaho
  109. Nampa, Idaho
  110. Nampa, Idaho
  111. Pocatello, Idaho
  112. Pocatello, Idaho
  113. Fort Wayne, Indiana
  114. Fort Wayne, Indiana
  115. Ames, Iowa
  116. Ames, Iowa
  117. Ames, Iowa
  118. Ames, Iowa
  119. Ankeny, Iowa
  120. West Des Moines, Iowa
  121. West Des Moines, Iowa
  122. El Dorado, Kansas
  123. Kansas City, Kansas
  124. Newton, Kansas
  125. Wichita, Kansas
  126. Wichita, Kansas
  127. Owensboro, Kentucky
  128. Owensboro, Kentucky
  129. Alexandria, Louisiana
  130. Alexandria, Louisiana
  131. Covington, Louisiana
  132. Gretna, Louisiana
  133. Lafayette, Louisiana
  134. Metairie, Louisiana
  135. New Orleans, Louisiana
  136. New Orleans, Louisiana
  137. New Orleans, Louisiana
  138. New Orleans, Louisiana
  139. New Orleans, Louisiana
  140. New Orleans, Louisiana
  141. New Orleans, Louisiana
  142. New Orleans, Louisiana
  143. Slidell, Louisiana
  144. Boston, Massachusetts
  145. Boston, Massachusetts
  146. Detroit, Michigan
  147. Detroit, Michigan
  148. Detroit, Michigan
  149. Southfield, Michigan
  150. Blaine, Minnesota
  151. Coon Rapids, Minnesota
  152. Coon Rapids, Minnesota
  153. Coon Rapids, Minnesota
  154. Fridley, Minnesota
  155. Maple Grove, Minnesota
  156. Minneapolis, Minnesota
  157. Minneapolis, Minnesota
  158. Minneapolis, Minnesota
  159. Gulfport, Mississippi
  160. Saint Louis, Missouri
  161. Saint Louis, Missouri
  162. Saint Louis, Missouri
  163. Saint Louis, Missouri
  164. Butte, Montana
  165. Great Falls, Montana
  166. Helena, Montana
  167. Kalispell, Montana
  168. Missoula, Montana
  169. Grand Island, Nebraska
  170. Hastings, Nebraska
  171. Lincoln, Nebraska
  172. Lincoln, Nebraska
  173. Lincoln, Nebraska
  174. Norfolk, Nebraska
  175. Las Vegas, Nevada
  176. Las Vegas, Nevada
  177. Las Vegas, Nevada
  178. Camden, New Jersey
  179. Camden, New Jersey
  180. Camden, New Jersey
  181. Cherry Hill, New Jersey
  182. New Brunswick, New Jersey
  183. Newark, New Jersey
  184. Newark, New Jersey
  185. Newark, New Jersey
  186. Newark, New Jersey
  187. Sewell, New Jersey
  188. Albuquerque, New Mexico
  189. Albuquerque, New Mexico
  190. East Setauket, New York
  191. East Setauket, New York
  192. East Setauket, New York
  193. Endwell, New York
  194. Flushing, New York
  195. Flushing, New York
  196. Fresh Meadows, New York
  197. Hollis, New York
  198. Jackson Heights, New York
  199. Johnson City, New York
  200. Mineola, New York
  201. Mineola, New York
  202. Mineola, New York
  203. Mineola, New York
  204. New Hyde Park, New York
  205. New York, New York
  206. New York, New York
  207. New York, New York
  208. New York, New York
  209. New York, New York
  210. New York, New York
  211. Rochester, New York
  212. Stony Brook, New York
  213. Durham, North Carolina
  214. Durham, North Carolina
  215. Durham, North Carolina
  216. Durham, North Carolina
  217. Pinehurst, North Carolina
  218. Pinehurst, North Carolina
  219. Raleigh, North Carolina
  220. Seven Lakes, North Carolina
  221. Southern Pines, North Carolina
  222. Southern Pines, North Carolina
  223. Dayton, Ohio
  224. Englewood, Ohio
  225. Yukon, Oklahoma
  226. Erie, Pennsylvania
  227. Erie, Pennsylvania
  228. Erie, Pennsylvania
  229. Erie, Pennsylvania
  230. Hershey, Pennsylvania
  231. Hershey, Pennsylvania
  232. Philadelphia, Pennsylvania
  233. Philadelphia, Pennsylvania
  234. West Reading, Pennsylvania
  235. West Reading, Pennsylvania
  236. West Reading, Pennsylvania
  237. Charleston, South Carolina
  238. Charleston, South Carolina
  239. Greenville, South Carolina
  240. Greenville, South Carolina
  241. Greenville, South Carolina
  242. Summerville, South Carolina
  243. Summerville, South Carolina
  244. Clarksville, Tennessee
  245. Knoxville, Tennessee
  246. Arlington, Texas
  247. Austin, Texas
  248. Beaumont, Texas
  249. Beaumont, Texas
  250. Beaumont, Texas
  251. Beaumont, Texas
  252. Burleson, Texas
  253. Dallas, Texas
  254. Dickinson, Texas
  255. Fort Worth, Texas
  256. Fort Worth, Texas
  257. Galveston, Texas
  258. Georgetown, Texas
  259. Georgetown, Texas
  260. Georgetown, Texas
  261. Georgetown, Texas
  262. Grapevine, Texas
  263. Houston, Texas
  264. Houston, Texas
  265. Houston, Texas
  266. Houston, Texas
  267. Houston, Texas
  268. Houston, Texas
  269. Houston, Texas
  270. Houston, Texas
  271. Houston, Texas
  272. Houston, Texas
  273. Lampasas, Texas
  274. Lampasas, Texas
  275. League City, Texas
  276. Longview, Texas
  277. Longview, Texas
  278. Longview, Texas
  279. Longview, Texas
  280. McAllen, Texas
  281. Plano, Texas
  282. San Antonio, Texas
  283. San Antonio, Texas
  284. Tomball, Texas
  285. Weatherford, Texas
  286. Salt Lake City, Utah
  287. Salt Lake City, Utah
  288. Salt Lake City, Utah
  289. Salt Lake City, Utah
  290. Salt Lake City, Utah
  291. Salt Lake City, Utah
  292. Salt Lake City, Utah
  293. Salt Lake City, Utah
  294. Norfolk, Virginia
  295. Norfolk, Virginia
  296. Richmond, Virginia
  297. Richmond, Virginia
  298. Richmond, Virginia
  299. Richmond, Virginia
  300. Richmond, Virginia
  301. Richmond, Virginia
  302. Richmond, Virginia
  303. Virginia Beach, Virginia
  304. Seattle, Washington
  305. Seattle, Washington
  306. Seattle, Washington
  307. Seattle, Washington
  308. Seattle, Washington
  309. Seattle, Washington
  310. Seattle, Washington
  311. Shoreline, Washington
  312. Tacoma, Washington
  313. Tacoma, Washington
  314. Tacoma, Washington
  315. Tacoma, Washington
  316. Tacoma, Washington
  317. Huntington, West Virginia
  318. Huntington, West Virginia
  319. Huntington, West Virginia
  320. Huntington, West Virginia
  321. Marshfield, Wisconsin
  322. Marshfield, Wisconsin
  323. San Miguel de Tucuman, Tucuman
  324. San Miguel de Tucuman, Tucuman
  325. Buenos Aires,
  326. Caba,
  327. Caba,
  328. North Adelaide, South Australia
  329. Clayton, Victoria
  330. Geelong, Victoria
  331. Sorocaba, SP
  332. Montreal, Quebec
  333. Quebec,
  334. Osorno, Región DE LOS Lagos
  335. Santiago, Región Metropolitana
  336. Santiago, Región Metropolitana
  337. Santiago, Región Metropolitana
  338. Santiago, Región Metropolitana
  339. Santiago, Región Metropolitana
  340. Santiago, Región Metropolitana
  341. Santiago, Región Metropolitana
  342. Aarhus N,
  343. Hillerod,
  344. Hvidovre,
  345. Odense C,
  346. Helsinki,
  347. Kokkola,
  348. Oulu,
  349. Pori,
  350. Seinajoki,
  351. Tampere,
  352. Turku,
  353. Fujisawa, Kanagawa
  354. Hoofddorp,
  355. Utrecht,
  356. Utrecht,
  357. Auckland,
  358. Christchurch,
  359. Christchurch,
  360. Wellington,
  361. Bloemfontein, FREE State
  362. Hillbrow, Johannesburg, Gauteng
  363. Johannesburg, Gauteng
  364. Soshanguve, Gauteng
  365. Soweto, Gauteng
  366. Khayelitsha, Western CAPE
  367. Parow Valley, Western CAPE
  368. Cape Town,
  369. Worcester,
  370. Santiago de Compostela, A Coruna
  371. Antequera, Malaga
  372. Madrid,
  373. Madrid,
  374. Mostoles,
  375. Valencia,
  376. Hsinchu City,
  377. Kaohsiung,
  378. Taipei City,
  379. Taipei,
  380. Taoyuan,
Female
18 Years+
years
MULTIPLE SITES
Respiratory Tract InfectionA Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults
NCT03572062
  1. South Brisbane, Queensland
  2. South Brisbane, Queensland
  3. Geelong, Victoria
  4. Fountain Hills, Arizona
  5. San Diego, California
  6. Coral Gables, Florida
  7. South Miami, Florida
  8. Peoria, Illinois
  9. Fremont, Nebraska
  10. Omaha, Nebraska
  11. Omaha, Nebraska
  12. Rochester, New York
  13. Rochester, New York
  14. South Jordan, Utah
  15. Adamstown, New South Wales
  16. Maroubra, New South Wales
  17. Merewether, New South Wales
  18. Sydney, New South Wales
  19. Sydney, New South Wales
  20. Westmead, New South Wales
  21. Westmead, New South Wales
  22. Sherwood, Queensland
  23. Box Hill, Victoria
  24. Box Hill, Victoria
  25. Camberwell, Victoria
  26. Camberwell, Victoria
  27. Clayton, Victoria
  28. Clayton, Victoria
  29. Geelong, Victoria
  30. Ivanhoe, Victoria
  31. Murdoch, Western Australia
  32. Murdoch, Western Australia
  33. Nedlands, Western Australia
  34. Nedlands, Western Australia
ALL GENDERS
65 Years+
years
MULTIPLE SITES
Respiratory Tract InfectionA PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN
NCT04032093
  1. Santiago, Region Metropolitana
  2. Birmingham, Alabama
  3. Birmingham, Alabama
  4. Birmingham, Alabama
  5. Cullman, Alabama
  6. Cullman, Alabama
  7. Cullman, Alabama
  8. Phoenix, Arizona
  9. Tucson, Arizona
  10. Tucson, Arizona
  11. Chowchilla, California
  12. Huntington Park, California
  13. Huntington Park, California
  14. Los Angeles, California
  15. Los Angeles, California
  16. Madera, California
  17. Madera, California
  18. Madera, California
  19. Madera, California
  20. Aurora, Colorado
  21. Aurora, Colorado
  22. Aurora, Colorado
  23. Aurora, Colorado
  24. Aurora, Colorado
  25. Aurora, Colorado
  26. Aurora, Colorado
  27. Atlanta, Georgia
  28. Atlanta, Georgia
  29. Blackfoot, Idaho
  30. Blackfoot, Idaho
  31. Blackfoot, Idaho
  32. Idaho Falls, Idaho
  33. Idaho Falls, Idaho
  34. Idaho Falls, Idaho
  35. Idaho Falls, Idaho
  36. Idaho Falls, Idaho
  37. Idaho Falls, Idaho
  38. Nampa, Idaho
  39. Nampa, Idaho
  40. Nampa, Idaho
  41. Nampa, Idaho
  42. Pocatello, Idaho
  43. Pocatello, Idaho
  44. Ankeny, Iowa
  45. West Des Moines, Iowa
  46. West Des Moines, Iowa
  47. El Dorado, Kansas
  48. Hutchinson, Kansas
  49. Alexandria, Louisiana
  50. Gretna, Louisiana
  51. Marrero, Louisiana
  52. Metairie, Louisiana
  53. Metairie, Louisiana
  54. New Orleans, Louisiana
  55. New Orleans, Louisiana
  56. Boston, Massachusetts
  57. Blaine, Minnesota
  58. Coon Rapids, Minnesota
  59. Coon Rapids, Minnesota
  60. Coon Rapids, Minnesota
  61. Coon Rapids, Minnesota
  62. Minneapolis, Minnesota
  63. Biloxi, Mississippi
  64. Gulfport, Mississippi
  65. Gulfport, Mississippi
  66. Gulfport, Mississippi
  67. Saint Louis, Missouri
  68. Saint Louis, Missouri
  69. Saint Louis, Missouri
  70. Missoula, Montana
  71. Missoula, Montana
  72. Lincoln, Nebraska
  73. Lincoln, Nebraska
  74. Lincoln, Nebraska
  75. Norfolk, Nebraska
  76. Henderson, Nevada
  77. Las Vegas, Nevada
  78. Albuquerque, New Mexico
  79. Albuquerque, New Mexico
  80. Albuquerque, New Mexico
  81. Binghamton, New York
  82. Endwell, New York
  83. Hempstead, New York
  84. Johnson City, New York
  85. Johnson City, New York
  86. Mineola, New York
  87. Mineola, New York
  88. Mineola, New York
  89. Mineola, New York
  90. Rochester, New York
  91. Rochester, New York
  92. Durham, North Carolina
  93. Durham, North Carolina
  94. Durham, North Carolina
  95. Durham, North Carolina
  96. Dayton, Ohio
  97. Dayton, Ohio
  98. Englewood, Ohio
  99. Kettering, Ohio
  100. Summerville, South Carolina
  101. Summerville, South Carolina
  102. Summerville, South Carolina
  103. Beaumont, Texas
  104. Beaumont, Texas
  105. Beaumont, Texas
  106. Beaumont, Texas
  107. Fort Worth, Texas
  108. Fort Worth, Texas
  109. Galveston, Texas
  110. Georgetown, Texas
  111. Georgetown, Texas
  112. Georgetown, Texas
  113. Georgetown, Texas
  114. Houston, Texas
  115. Houston, Texas
  116. Houston, Texas
  117. Houston, Texas
  118. Houston, Texas
  119. Houston, Texas
  120. Lampasas, Texas
  121. Lampasas, Texas
  122. Longview, Texas
  123. Longview, Texas
  124. Longview, Texas
  125. McAllen, Texas
  126. Pharr, Texas
  127. Plano, Texas
  128. Plano, Texas
  129. Round Rock, Texas
  130. Tomball, Texas
  131. Murray, Utah
  132. Salt Lake City, Utah
  133. Salt Lake City, Utah
  134. Salt Lake City, Utah
  135. Salt Lake City, Utah
  136. Salt Lake City, Utah
  137. Salt Lake City, Utah
  138. Richmond, Virginia
  139. Richmond, Virginia
  140. Huntington, West Virginia
  141. Huntington, West Virginia
  142. Huntington, West Virginia
  143. Huntington, West Virginia
  144. San Miguel de Tucuman, Tucuman
  145. San Miguel de Tucuman, Tucuman
  146. Cordoba,
  147. Salta,
  148. San Miguel de Tucuman,
  149. Santiago, Region Metropolitana
  150. Osorno, Región DE LOS Lagos
  151. Santiago, Región Metropolitana
  152. Santiago, Región Metropolitana
  153. Santiago, Región Metropolitana
  154. Santiago, Región Metropolitana
  155. Santiago, RM
  156. Soweto, Gauteng
  157. Soweto, Gauteng
Female
18 Years+
years
MULTIPLE SITES
Respiratory Tract InfectionA STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS
NCT04071158
  1. Stockbridge, Georgia
  2. Honolulu, Hawaii
  3. Wichita, Kansas
  4. Saint Louis, Missouri
  5. Omaha, Nebraska
  6. Oklahoma City, Oklahoma
  7. Warwick, Rhode Island
  8. Dakota Dunes, South Dakota
  9. Austin, Texas
  10. Fort Worth, Texas
  11. Houston, Texas
  12. San Antonio, Texas
  13. San Antonio, Texas
  14. Tomball, Texas
  15. Tomball, Texas
  16. Salt Lake City, Utah
  17. Salt Lake City, Utah
  18. South Jordan, Utah
Female
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN
Official Title  ICMJE A PHASE 2B, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS
Brief Summary This Phase 2b study will evaluate the safety, tolerability, and immunogenicity of an RSV vaccine in pregnant participants who receive either one of 2 dose levels of the vaccine, formulated with or without aluminum hydroxide, or placebo, and investigate safety and characteristics of antibodies in their infants.
Detailed Description This Phase 2b, multicenter, randomized, placebo-controlled study will evaluate the safety, tolerability, and immunogenicity of a respiratory syncytial virus stabilized prefusion F subunit vaccine (RSV vaccine) in pregnant participants who receive either one of 2 dose levels of the vaccine, formulated with or without aluminum hydroxide, or placebo, as well as assess safety and characteristics of transplacentally transferred antibodies in their infants.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
This is an observer-blinded study. Study staff dispensing and administering the vaccine will be unblinded, but the participant and all other study personnel, including the principal investigator, will be blinded.
Primary Purpose: Prevention
Condition  ICMJE Respiratory Tract Infection
Intervention  ICMJE
  • Biological: RSV vaccine
    RSV vaccine
  • Biological: Placebo
    Normal saline solution for injection (0.9% sodium chloride injection)
Study Arms  ICMJE
  • Experimental: RSV dose with aluminum hydroxide
    RSV vaccine with aluminum hydroxide
    Intervention: Biological: RSV vaccine
  • Experimental: RSV dose without aluminum hydroxide
    RSV vaccine without aluminum hydroxide
    Intervention: Biological: RSV vaccine
  • Experimental: Higher RSV dose with aluminum hydroxide
    Higher dose level RSV vaccine with aluminum hydroxide
    Intervention: Biological: RSV vaccine
  • Experimental: Higher RSV dose without aluminum hydroxide
    Higher dose level RSV vaccine without aluminum hydroxide
    Intervention: Biological: RSV vaccine
  • Placebo Comparator: Placebo dose
    Normal saline solution for injection (0.9% sodium chloride injection)
    Intervention: Biological: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Estimated Enrollment  ICMJE
 (submitted: July 22, 2019)
650
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE October 22, 2021
Estimated Primary Completion Date October 22, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria - Maternal participants:

  • Healthy women 18 to 49 years of age between 24 and 36 weeks of gestation on the day of planned vaccination, with an uncomplicated pregnancy, who are at no known increased risk for complications, and whose fetus has no significant abnormalities observed on ultrasound.
  • Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  • Receiving prenatal standard of care.
  • Had an ultrasound performed at >=18 weeks of pregnancy.
  • Had a negative urinalysis for protein and glucose at the screening visit. Trace protein in the urine is acceptable if the blood pressure is also normal.
  • Determined by medical history, physical examination, screening laboratory assessment, and clinical judgment to be appropriate for inclusion in the study.
  • Documented negative human immunodeficiency virus antibody, hepatitis B virus surface antigen, hepatitis C virus antibody, and syphilis tests at the screening visit.
  • Body mass index of </=40 kg/m2 at the time of the screening visit.
  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent document and in this protocol.
  • Expected to be available for the duration of the study and willing to give informed consent for her infant to participate in the study.

Inclusion Criteria - Infant Participants:

  • Evidence of a signed and dated ICD signed by the parent(s).
  • Parent(s) willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria - Maternal Participants:

  • Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction to any component of the investigational product or any related vaccine.
  • History of latex allergy.
  • History of any severe allergic reaction.
  • Participants with known or suspected immunodeficiency.
  • Current pregnancy resulting from in vitro fertilization or other assisted reproductive technology.
  • A prior history of or known current pregnancy complications or abnormalities that will increase the risk associated with the participant's participation in and completion of the study.
  • Major illness of the mother or conditions of the fetus that, in the investigator's judgment, will substantially increase the risk associated with the participant's participation in, and completion of, the study or could preclude the evaluation of the participant's response.
  • Participant with a history of autoimmune disease or an active autoimmune disease requiring therapeutic intervention including but not limited to systemic or cutaneous lupus erythematosus, autoimmune arthritis/rheumatoid arthritis, Guillain-Barré syndrome, multiple sclerosis, Sjögren's syndrome, idiopathic thrombocytopenia purpura, glomerulonephritis, autoimmune thyroiditis, giant cell arteritis (temporal arteritis), psoriasis, and insulin-dependent diabetes mellitus (type 1).
  • Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
  • Participation in other studies involving investigational drug(s) within 28 days prior to study entry and/or during study participation.
  • Participants who receive treatment with immunosuppressive therapy including cytotoxic agents or systemic corticosteroids (such as for cancer or an autoimmune disease), or planned receipt of such treatment or agents during study participation. If systemic corticosteroids have been administered short term (<14 days) for treatment of an acute illness, participants should not be enrolled into the study until corticosteroid therapy has been discontinued for at least 30 days before investigational product administration. Inhaled/nebulized, intra articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.
  • Current alcohol abuse or illicit drug use.
  • Receipt of blood or plasma products or immunoglobulin, from 60 days before investigational product administration, or planned receipt through delivery, with 1 exception, Rho(D) immune globulin (eg, RhoGAM), which can be given at any time.
  • Previous vaccination with any licensed or investigational RSV vaccine or planned receipt during study participation.
  • Laboratory test results at the screening visit outside the normal reference value for pregnant women according to their trimester in pregnancy.
  • Participants who are breastfeeding at the time of the screening visit.

Exclusion Criteria - Infant Participants:

? Infant who is a direct descendant (eg, child or grandchild) of the study personnel.

Sex/Gender  ICMJE
Sexes Eligible for Study:Female
Gender Based Eligibility:Yes
Gender Eligibility Description:Healthy women 18 to 49 years of age who are between 24 and 36 weeks of gestation on the day of planned vaccination, with an uncomplicated pregnancy, who are at no known increased risk for complications, and whose fetus has no significant abnormalities observed on ultrasound
Ages  ICMJE 18 Years to 49 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Argentina,   Chile,   New Zealand,   South Africa,   United States
Removed Location Countries Australia
 
Administrative Information
NCT Number  ICMJE NCT04032093
Other Study ID Numbers  ICMJE C3671003
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date January 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP